6 unknown, 4 completed, 2 enrolling by invitation, 1 recruiting. 14 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Unknown 6, Completed 4, Enrolling by invitation 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 8 | Unknown 4, Enrolling by invitation 2, Completed 1, Withdrawn 1 |
Follow Keratoconus: new trials by email Literature Review of Keratoconus trials Research Report on Keratoconus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TN-001 Topical Eyedrops for Keratoconus Low-dose TGF-B3 and Dexamethasone Sodium Phosphate, High-dose TGF-B3 and Dexamethasone Sodium Phosphate - Keratoconus | Phase 1 / Phase 2 | Enrolling by invitation | TheiaNova Ltd. | 20 | 2025-12-23 | 2026-02-04 |
| Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops - Keratoconus | Phase 1 / Phase 2 | Enrolling by invitation | Maanasa Indaram, MD | 20 | 2025-04-11 | 2026-09-11 |
| PXL-Platinum 330 in Eyes With Corneal Thinning Conditions Pulsed or continuous lighting - Corneal Thinning, Keratoconus | Phase 1 / Phase 2 | Withdrawn | Vishal Jhanji | 2023-08-15 | 2023-10-05 | |
| Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus NXL Energy 1, NXL Energy 2, NXL Energy 3 - Progressive Keratoconus | Phase 1 / Phase 2 | Unknown | Glaukos Corporation | 150 | 2022-03-08 | 2024-07-08 |
| Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution PXL-330 Platinum device for crosslinking with Peschke riboflavin solution - Keratoconus, Pellucid Marginal Corneal Degeneration | Phase 1 | Completed | Cornea Associates of Texas | 249 | 2021-02-01 | 2025-02-11 |
| Safety and Effectiveness of the PXL-Platinum 330 System PXL-330 Platinum device for crosslinking with Peschke riboflavin solution - Corneal Ectasia, Keratoconus | Phase 1 / Phase 2 | Unknown | Colorado Eye Consultants/Cornea Consultants of Colorado | 300 | 2020-06-01 | 2022-01-25 |
| Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution PXL-330 Platinum device for crosslinking with Peschke riboflavin solution - Keratoconus, Pellucid Marginal Corneal Degeneration | Phase 1 | Completed | Cornea Associates of Texas | 200 | 2020-01-10 | 2022-10-19 |
| Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution - Keratoconus, Unstable, Bacterial Keratitis | Phase 1 | Recruiting | Pacific Clear Vision Institute | 300 | 2019-09-01 | 2024-11-12 |
| Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients IVMED-80, Placebo - Keratoconus, Corneal Ectasia | Phase 1 / Phase 2 | Completed | iVeena Delivery Systems, Inc. | 38 | 2019-02-08 | 2022-02-15 |
| Adapted Fluence Settings for Corneal Collagen Cross-linking in Mild to Moderate Progressive Keratoconus adjusted corneal collagen cross-linking, accelerated corneal collagen cross-linking, riboflavin 0.1% combined with dextran 20 % - Keratoconus | Phase 1 / Phase 2 | Unknown | Tehran University of Medical Sciences | 40 | 2014-08-01 | 2015-07-23 |
| Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2 Riboflavin 0.1% ophthalmic solution, CCL-VARIO UV lamp, CCL-VARIO at 18 mW/cm2 - Keratoconus, Corneal Ectasia | Phase 1 | Unknown | Robert Mack, M.D. | 100 | 2013-10-01 | 2015-12-14 |
| Treatment of Keratoconus With PALK Versus PK Penetrating keratoplasty, Pachymetry and Excimer laser assisted lamellar keratoplasty, Treatment posterior to surgery - Keratoconus | Phase 1 | Completed | Instituto de Oftalmología Fundación Conde de Valenciana | 28 | 2013-06-01 | 2015-12-09 |
| Clinical and Structural Outcome of Conventional Versus Accelerated Corneal Collagen Cross-linking (CXL). UV-X 1000 (3 mW/cm²), UV-X 2000 (9 mW/cm²), riboflavin with hydroxypropyl methylcellulose - Keratoconus, Corneal Ectasia | Phase 1 / Phase 2 | Unknown | Oslo University Hospital | 40 | 2012-08-01 | 2016-08-30 |
| Outcomes in a Comparison of Manual Penetrating Keratoplasty and the IntraLase® Enabled Keratoplasty Penetrating keratoplasty with IntraLase, Penetrating keratoplasty with vacuum trephine - Keratoconus | Phase 1 | Unknown | Hospital Oftalmologico de Sorocaba | 60 | 2007-08-01 | 2007-12-03 |
Corneal Diseases (14) · Eye Diseases (14) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1)
Riboflavin (3) · Keratoplasty, Penetrating (2) · Ophthalmic Solutions (2) · Calcium Dobesilate (1) · Chromatin Immunoprecipitation Sequencing (1) · Corneal Cross-Linking (1) · Heart Rate (1) · Hypromellose Derivatives (1) · Radiation (1) · Radiotherapy (1) · Subgingival Curettage (1) · dexamethasone 21-phosphate (1) · prednisolone acetate (1)
Cornea Associates of Texas (2) · Colorado Eye Consultants/Cornea Consultants of Colorado (1) · Glaukos Corporation (1) · Hospital Oftalmologico de Sorocaba (1) · Instituto de Oftalmología Fundación Conde de Valenciana (1) · Maanasa Indaram, MD (1) · Oslo University Hospital (1) · Pacific Clear Vision Institute (1) · Robert Mack, M.D. (1) · Tehran University of Medical Sciences (1) · TheiaNova Ltd. (1) · Vishal Jhanji (1) · iVeena Delivery Systems, Inc. (1)
United States (8) · Australia (1) · Brazil (1) · Iran (1) · Mexico (1)
Arturo Chayet, MD (1) · Balamurali K. Ambati, MD, PhD (1) · Elissandro M Silva, Lindoso (1) · Enrique Graue Hernandez, MD, MsC (1) · Fateme Alipour, MD (1) · Maanasa Indaram, MD (1) · Robert J Mack, M.D. (1) · S. Lance Forstot, M.D. (1) · Tyrone McCall, MD (1) · Vishal Jhanji, MD (1)